Regeneron Pharmaceuticals, Inc.
Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies
Last updated:
Abstract:
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human interleukin-6 receptor (hIL-6R). The formulations may contain, in addition to an anti-hIL-6R antibody, at least one amino acid, at least one sugar, and/or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Status:
Grant
Type:
Utility
Filling date:
9 Aug 2018
Issue date:
24 Aug 2021